"Global Companion Diagnostics Market Overview:
Global Companion Diagnostics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Companion Diagnostics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Companion Diagnostics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Companion Diagnostics Market:
The Companion Diagnostics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Companion Diagnostics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Companion Diagnostics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Companion Diagnostics market has been segmented into:
Real Time-Polymerase Chain Reactions (PCR
By Application, Companion Diagnostics market has been segmented into:
Oncology
Cardiovascular Diseases
Infectious Diseases
Neurological Diseases and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Companion Diagnostics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Companion Diagnostics market.
Top Key Players Covered in Companion Diagnostics market are:
F. Hoffmann-La Roche AG
Agilent Technologiesinc.
QIAGEN N.V
Abbott Laboratoriesinc.
Almac Group
Danaher Corporation
Illuminainc.
bioMérieux SA
Myriad Geneticsinc.
Sysmex Corporation
Thermo Fisher Scientific Inc.
Abnova Corporation
Guardant Healthinc.
Icon Plc.
Biogenex Laboratoriesinc.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Companion Diagnostics Market by Type
4.1 Companion Diagnostics Market Snapshot and Growth Engine
4.2 Companion Diagnostics Market Overview
4.3 Real Time-Polymerase Chain Reactions (PCR
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Real Time-Polymerase Chain Reactions (PCR: Geographic Segmentation Analysis
Chapter 5: Companion Diagnostics Market by Application
5.1 Companion Diagnostics Market Snapshot and Growth Engine
5.2 Companion Diagnostics Market Overview
5.3 Oncology
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oncology: Geographic Segmentation Analysis
5.4 Cardiovascular Diseases
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cardiovascular Diseases: Geographic Segmentation Analysis
5.5 Infectious Diseases
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Infectious Diseases: Geographic Segmentation Analysis
5.6 Neurological Diseases and Others
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Neurological Diseases and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Companion Diagnostics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 F. HOFFMANN-LA ROCHE AG
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 AGILENT TECHNOLOGIESINC.
6.4 QIAGEN N.V
6.5 ABBOTT LABORATORIESINC.
6.6 ALMAC GROUP
6.7 DANAHER CORPORATION
6.8 ILLUMINAINC.
6.9 BIOMÉRIEUX SA
6.10 MYRIAD GENETICSINC.
6.11 SYSMEX CORPORATION
6.12 THERMO FISHER SCIENTIFIC INC.
6.13 ABNOVA CORPORATION
6.14 GUARDANT HEALTHINC.
6.15 ICON PLC.
6.16 AND BIOGENEX LABORATORIESINC.
Chapter 7: Global Companion Diagnostics Market By Region
7.1 Overview
7.2. North America Companion Diagnostics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Real Time-Polymerase Chain Reactions (PCR
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oncology
7.2.5.2 Cardiovascular Diseases
7.2.5.3 Infectious Diseases
7.2.5.4 Neurological Diseases and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Companion Diagnostics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Real Time-Polymerase Chain Reactions (PCR
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oncology
7.3.5.2 Cardiovascular Diseases
7.3.5.3 Infectious Diseases
7.3.5.4 Neurological Diseases and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Companion Diagnostics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Real Time-Polymerase Chain Reactions (PCR
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oncology
7.4.5.2 Cardiovascular Diseases
7.4.5.3 Infectious Diseases
7.4.5.4 Neurological Diseases and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Companion Diagnostics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Real Time-Polymerase Chain Reactions (PCR
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oncology
7.5.5.2 Cardiovascular Diseases
7.5.5.3 Infectious Diseases
7.5.5.4 Neurological Diseases and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Companion Diagnostics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Real Time-Polymerase Chain Reactions (PCR
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oncology
7.6.5.2 Cardiovascular Diseases
7.6.5.3 Infectious Diseases
7.6.5.4 Neurological Diseases and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Companion Diagnostics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Real Time-Polymerase Chain Reactions (PCR
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oncology
7.7.5.2 Cardiovascular Diseases
7.7.5.3 Infectious Diseases
7.7.5.4 Neurological Diseases and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Companion Diagnostics Scope:
|
Report Data
|
Companion Diagnostics Market
|
|
Companion Diagnostics Market Size in 2025
|
USD XX million
|
|
Companion Diagnostics CAGR 2025 - 2032
|
XX%
|
|
Companion Diagnostics Base Year
|
2024
|
|
Companion Diagnostics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
F. Hoffmann-La Roche AG, Agilent Technologiesinc., QIAGEN N.V, Abbott Laboratoriesinc., Almac Group, Danaher Corporation, Illuminainc., bioMérieux SA, Myriad Geneticsinc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Healthinc., Icon Plc., and Biogenex Laboratoriesinc..
|
|
Key Segments
|
By Type
Real Time-Polymerase Chain Reactions (PCR
By Applications
Oncology
Cardiovascular Diseases
Infectious Diseases
Neurological Diseases and Others
|
